Sulodexide
Based on 1 Customer Validation
Sulodexide is a mixture of glycosaminoglycans available in soft capsule form for oral administration. It is composed of low molecular weight heparin (80%) and dermatan sulfate (20%). Sulodexide exhibits antithrombotic activity through interaction with antithrombin III (AT III) and heparin cofactor II (HC II), and inhibition of thrombin formation. Sulodexide exhibits profibrinolytic activity through release of tissue plasminogen activator (tPA). Sulodexide exhibits endothelial protective and anti-inflammatory effect, ameliorates chronic venous disease. Sulodexide is a glycosaminoglycan mixture available in soft gelatin capsule form for oral administration.
For research use only. We do not sell to patients.
- CAS No.: 57821-29-1
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Sulodexide (0–200 μg/mL, 24 hours) promotes fibronectin and collagen type III synthesis in mouse mesangial cells[2]. Sulodexide (50 µg/mL, 48 hours) significantly inhibits capillarization marker expression in LSECs[4]. Note: This product is in soft capsule form and has viscous contents.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Mouse mesangial cells (diabetic nephropathy)
-
Concentration:0–200 μg/mL
-
Incubation Time:24 hours
-
Result:Increased synthesis of fibronectin and collagen type III in cells, further enhanced under high glucose conditions.
-
Cell Line:Mouse liver sinusoidal endothelial cells (LSECs; liver fibrosis)
-
Concentration:50 µg/mL
-
Incubation Time:48 hours
-
Result:Significantly reduced expression of capillarization markers Edn1 and CD34.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Streptozotocin (HY-13753)-induced type I diabetic nephropathy in C57BL/6 mice model[2]
-
Dosage:1 mg/kg
-
Administration:Oral gavage (p.o.), once daily for 12 weeks
-
Result:Significantly reduced urinary albumin levels, improved renal function, increased GBM perlecan expression, reduced collagen I and IV deposition, and ERK activation.
-
Animal Model:Oxygen-induced retinopathy (OIR) model in ICR mice[3]
-
Dosage:5 mg/kg and 15 mg/kg
-
Administration:Intraperitoneal injection (i.p.), once daily for 5 days
-
Result:Significantly reduced avascular area, decreased neovascular tufts and lumens. Significantly inhibited expression of MMP-2, MMP-9, and VEGF
-
Animal Model:Thioacetamide (HY-Y0698)-induced liver fibrosis in C57BL/6 mice model[4]
-
Dosage:20 mg/kg
-
Administration:Intragastric administration (i.g.), once daily for 4 weeks
-
Result:Significantly reduced expression of fibrosis markers (Col1a1 and α-SMA), decreased hydroxyproline levels, and inhibited ECM deposition in liver tissue.
-
Animal Model:LPS (HY-D1056)-induced endotoxemia in C57BL/6J mice model[5]
-
Dosage:40 mg/kg
-
Administration:Intragastric administration (i.g.), single dose
-
Result:Significantly reduced plasma Syndecan-1 (SDC1) levels, increased survival rate, reduced lung injury, and restored endothelial glycocalyx damage.
Chemical Information
-
CAS No. 57821-29-1
-
Appearance Solid-Liquid Mixture
-
Color Colorless to light yellow
-
SMILES
[Sulodexide]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : < 1 mg/mL (insoluble)
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Andreozzi GM. Sulodexide in the treatment of chronic venous disease. Am J Cardiovasc Drugs. 2012 Apr 1;12(2):73-81. [Content Brief]
[2]. Yung S, et al. Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin-induced type I diabetic nephropathy[J]. PloS one, 2013, 8(1): e54501. [Content Brief]
[3]. Jo H, et al. Sulodexide inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy[J]. BMB reports, 2014, 47(11): 637. [Content Brief]
[4]. Huang R, et al. Sulodexide attenuates liver fibrosis in mice by restoration of differentiated liver sinusoidal endothelial cell[J]. Biomedicine & Pharmacotherapy, 2023, 160: 114396. [Content Brief]
[5]. Ying J, et al. Sulodexide improves vascular permeability via glycocalyx remodelling in endothelial cells during sepsis[J]. Frontiers in immunology, 2023, 14: 1172892. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)